|
1
|
Rindi G, Klimstra DS, Abedi-Ardekani B,
Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M,
El-Naggar AK, et al: A common classification framework for
neuroendocrine neoplasms: An international agency for research on
cancer (IARC) and world health organization (WHO) expert consensus
proposal. Mod Pathol. 31:1770–1786. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fisch D and Christopoulos P: Double
trouble: Combined large-cell neuroendocrine and small-cell lung
carcinoma. Transl Cancer Res. 11:3006–3011. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kinslow CJ, May MS, Saqi A, et al:
Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based
Study. Clin Lung Cancer. 21:e99–e113. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ai L, Li J, Ye T, Wang W and Li Y:
Progressive neuroendocrine tumor of lung with combined categories
in metastatic site: A case report. Transl Cancer Res. 11:2438–2442.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yatabe Y, Dacic S, Borczuk AC, Warth A,
Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G,
Rekhtman N, et al: Best practices recommendations for diagnostic
immunohistochemistry in lung cancer. J Thorac Oncol. 14:377–407.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ganti AKP, Loo BW, Bassetti M, Blakely C,
Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M,
et al: Small cell lung cancer, version 2.2022, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
19:1441–1464. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang JT, Li Y, Yan LX, Zhu ZF, Dong XR,
Chu Q, Wu L, Zhang HM, Xu CW, Lin G, et al: Disparity in clinical
outcomes between pure and combined pulmonary large-cell
neuroendocrine carcinoma: A multi-center retrospective study. Lung
Cancer. 139:118–123. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Borczuk AC: Pulmonary neuroendocrine
tumors. Surg Pathol Clin. 13:35–55. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Raman V, Jawitz OK, Yang CJ, Voigt SL,
Tong BC, D'Amico TA and Harpole DH: Outcomes for surgery in large
cell lung neuroendocrine cancer. J Thorac Oncol. 14:2143–2151.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li M, Yang L and Lu H: Pulmonary combined
large cell neuroendocrine carcinoma. Pathol Oncol Res.
28:16107472022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Buium C, Negru S, Ionescu DN and Dediu M:
The unmet diagnostic and treatment needs in large cell
neuroendocrine carcinoma of the lung. Curr Oncol. 30:7218–7228.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kujtan L, Muthukumar V, Kennedy KF, Davis
JR, Masood A and Subramanian J: The role of systemic therapy in the
management of stage I large cell neuroendocrine carcinoma of the
lung. J Thorac Oncol. 13:707–714. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Niho S, Kenmotsu H, Sekine I, Ishii G,
Ishikawa Y, Noguchi M, Oshita F, Watanabe S, Nakajima R, Tada H and
Nagai K: Combination chemotherapy with irinotecan and cisplatin for
large-cell neuroendocrine carcinoma of the lung: A multicenter
phase II study. J Thorac Oncol. 8:980–984. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Le Treut J, Sault MC, Lena H, Souquet PJ,
Vergnenegre A, Le Caer H, Berard H, Boffa S, Monnet I, Damotte D
and Chouaid C: Multicentre phase II study of cisplatin-etoposide
chemotherapy for advanced large-cell neuroendocrine lung carcinoma:
The GFPC 0302 study. Ann Oncol. 24:1548–1552. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Prelaj A, Rebuzzi SE, Del Bene G, Giròn
Berrìos JR, Emiliani A, De Filippis L, Prete AA, Pecorari S, Manna
G, Ferrara C, et al: Evaluation of the efficacy of
cisplatin-etoposide and the role of thoracic radiotherapy and
prophylactic cranial irradiation in LCNEC. ERJ Open Res.
3:00128–2016. 2017. View Article : Google Scholar : PubMed/NCBI
|
